TransMedics Group (TMDX) Competitors

TransMedics Group logo
$94.19 -2.24 (-2.33%)
As of 03:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

TMDX vs. PEN, PODD, GMED, TFX, and HAE

Should you buy TransMedics Group stock or one of its competitors? TransMedics Group's main competitors and comparable companies include Penumbra (PEN), Insulet (PODD), Globus Medical (GMED), Teleflex (TFX), and Haemonetics (HAE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does TransMedics Group compare to Penumbra?

Penumbra (NYSE:PEN) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, TransMedics Group had 2 more articles in the media than Penumbra. MarketBeat recorded 5 mentions for TransMedics Group and 3 mentions for Penumbra. TransMedics Group's average media sentiment score of 0.37 beat Penumbra's score of 0.35 indicating that TransMedics Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Penumbra
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
TransMedics Group
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

TransMedics Group has a net margin of 19.85% compared to Penumbra's net margin of 10.06%. TransMedics Group's return on equity of 13.30% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
Penumbra10.06% 10.39% 8.09%
TransMedics Group 19.85%13.30%4.93%

88.9% of Penumbra shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 2.9% of Penumbra shares are held by insiders. Comparatively, 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

TransMedics Group has lower revenue, but higher earnings than Penumbra. TransMedics Group is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$1.40B9.00$177.69M$3.9780.70
TransMedics Group$727.65M4.60$190.29M$3.6926.13

Penumbra has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Penumbra presently has a consensus target price of $367.07, suggesting a potential upside of 14.57%. TransMedics Group has a consensus target price of $113.30, suggesting a potential upside of 17.49%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts plainly believe TransMedics Group is more favorable than Penumbra.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Penumbra
0 Sell rating(s)
14 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.18
TransMedics Group
0 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.42

Summary

TransMedics Group beats Penumbra on 11 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to Insulet?

Insulet (NASDAQ:PODD) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

TransMedics Group has a net margin of 19.85% compared to Insulet's net margin of 13.44%. Insulet's return on equity of 31.76% beat TransMedics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Insulet13.44% 31.76% 14.48%
TransMedics Group 19.85%13.30%4.93%

99.7% of TransMedics Group shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Insulet has higher revenue and earnings than TransMedics Group. Insulet is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insulet$2.71B3.59$247.10M$6.1422.80
TransMedics Group$727.65M4.60$190.29M$3.6926.13

In the previous week, Insulet had 5 more articles in the media than TransMedics Group. MarketBeat recorded 10 mentions for Insulet and 5 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.37 beat Insulet's score of 0.32 indicating that TransMedics Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insulet
2 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
TransMedics Group
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Insulet presently has a consensus target price of $185.04, indicating a potential upside of 32.19%. TransMedics Group has a consensus target price of $113.30, indicating a potential upside of 17.49%. Given Insulet's higher probable upside, analysts plainly believe Insulet is more favorable than TransMedics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insulet
1 Sell rating(s)
13 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.40
TransMedics Group
0 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.42

Insulet has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, TransMedics Group has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Summary

Insulet and TransMedics Group tied by winning 8 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to Globus Medical?

TransMedics Group (NASDAQ:TMDX) and Globus Medical (NYSE:GMED) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

TransMedics Group presently has a consensus price target of $113.30, indicating a potential upside of 17.49%. Globus Medical has a consensus price target of $96.08, indicating a potential upside of 36.03%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts plainly believe Globus Medical is more favorable than TransMedics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransMedics Group
0 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.42
Globus Medical
0 Sell rating(s)
7 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.63

Globus Medical has higher revenue and earnings than TransMedics Group. Globus Medical is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$727.65M4.60$190.29M$3.6926.13
Globus Medical$2.94B3.18$537.87M$4.0717.35

In the previous week, Globus Medical had 4 more articles in the media than TransMedics Group. MarketBeat recorded 9 mentions for Globus Medical and 5 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.37 beat Globus Medical's score of -0.04 indicating that TransMedics Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TransMedics Group
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Globus Medical
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 95.2% of Globus Medical shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by company insiders. Comparatively, 18.4% of Globus Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

TransMedics Group has a net margin of 19.85% compared to Globus Medical's net margin of 17.76%. Globus Medical's return on equity of 14.43% beat TransMedics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
TransMedics Group19.85% 13.30% 4.93%
Globus Medical 17.76%14.43%12.52%

TransMedics Group has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Globus Medical has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Summary

Globus Medical beats TransMedics Group on 11 of the 17 factors compared between the two stocks.

How does TransMedics Group compare to Teleflex?

TransMedics Group (NASDAQ:TMDX) and Teleflex (NYSE:TFX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, TransMedics Group and TransMedics Group both had 5 articles in the media. TransMedics Group's average media sentiment score of 0.37 beat Teleflex's score of 0.07 indicating that TransMedics Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TransMedics Group
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Teleflex
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

TransMedics Group has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Teleflex has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

TransMedics Group presently has a consensus target price of $113.30, indicating a potential upside of 17.49%. Teleflex has a consensus target price of $163.30, indicating a potential downside of 1.68%. Given TransMedics Group's higher probable upside, equities analysts clearly believe TransMedics Group is more favorable than Teleflex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransMedics Group
0 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.42
Teleflex
0 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.58

TransMedics Group has a net margin of 19.85% compared to Teleflex's net margin of 13.51%. TransMedics Group's return on equity of 13.30% beat Teleflex's return on equity.

Company Net Margins Return on Equity Return on Assets
TransMedics Group19.85% 13.30% 4.93%
Teleflex 13.51%10.57%4.96%

TransMedics Group has higher earnings, but lower revenue than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$727.65M4.60$190.29M$3.6926.13
Teleflex$1.99B3.31-$905.64M$8.2320.18

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 6.9% of TransMedics Group shares are held by company insiders. Comparatively, 0.7% of Teleflex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

TransMedics Group beats Teleflex on 10 of the 15 factors compared between the two stocks.

How does TransMedics Group compare to Haemonetics?

TransMedics Group (NASDAQ:TMDX) and Haemonetics (NYSE:HAE) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

TransMedics Group has higher earnings, but lower revenue than Haemonetics. TransMedics Group is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$727.65M4.60$190.29M$3.6926.13
Haemonetics$1.33B4.19$97.31M$2.2355.06

In the previous week, Haemonetics had 6 more articles in the media than TransMedics Group. MarketBeat recorded 11 mentions for Haemonetics and 5 mentions for TransMedics Group. Haemonetics' average media sentiment score of 0.40 beat TransMedics Group's score of 0.37 indicating that Haemonetics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TransMedics Group
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Haemonetics
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

TransMedics Group has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

TransMedics Group has a net margin of 19.85% compared to Haemonetics' net margin of 7.52%. Haemonetics' return on equity of 27.42% beat TransMedics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
TransMedics Group19.85% 13.30% 4.93%
Haemonetics 7.52%27.42%9.77%

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 2.1% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

TransMedics Group presently has a consensus price target of $113.30, suggesting a potential upside of 17.49%. Haemonetics has a consensus price target of $130.50, suggesting a potential upside of 6.29%. Given TransMedics Group's higher possible upside, equities research analysts clearly believe TransMedics Group is more favorable than Haemonetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransMedics Group
0 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.42
Haemonetics
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.85

Summary

Haemonetics beats TransMedics Group on 9 of the 17 factors compared between the two stocks.

Get TransMedics Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TMDX vs. The Competition

MetricTransMedics GroupHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.28B$5.84B$7.47B$11.50B
Dividend YieldN/A1.68%2.47%4.64%
P/E Ratio25.5938.4432.8329.61
Price / Sales4.504.717.935.27
Price / Cash23.9123.3720.8521.62
Price / Book5.944.134.383.66
Net Income$190.29M$143.14M$3.51B$394.15M
7 Day Performance2.38%-5.08%-5.94%-6.04%
1 Month Performance31.55%-5.40%-6.80%-8.42%
1 Year Performance-29.43%-1.10%-2.32%-8.13%

TransMedics Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TMDX
TransMedics Group
3.8965 of 5 stars
$94.19
-2.3%
$113.30
+20.3%
-17.6%$3.28B$727.65M25.59898
PEN
Penumbra
2.0344 of 5 stars
$320.57
-0.1%
$367.07
+14.5%
+15.1%$12.64B$1.56B80.754,700
PODD
Insulet
4.3054 of 5 stars
$145.16
-4.8%
$185.67
+27.9%
-58.0%$10.07B$3.19B23.645,400
GMED
Globus Medical
3.604 of 5 stars
$70.52
-2.3%
$96.08
+36.3%
-15.3%$9.34B$2.94B17.336,000
TFX
Teleflex
2.7631 of 5 stars
$157.40
+1.5%
$163.30
+3.8%
+54.4%$6.24B$2.26B19.1215,500

Related Companies and Tools


This page (NASDAQ:TMDX) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners